Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 4/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26501518 | 0.87 | CNR2 (0.38) | CNR2 | |
| SCHEMBL26501671 | 0.86 | CNR2 (0.33) | GLSHTTTDP1L3MBTL1CNR2 | |
| SCHEMBL26501672 | 0.84 | PANK3 (0.43) | GLSHTTPDE2ATDP1L3MBTL1 | |
| SCHEMBL26501676 | 0.83 | PANK3 (0.39) | GLSHTTTDP1L3MBTL1KEAP1 | |
| SCHEMBL26501674 | 0.82 | TAAR1 (0.36) | GLSHTTKEAP1NFE2L2F2 | |
| SCHEMBL26501785 | 0.81 | RAB9A (0.36) | HTTPDE2ATDP1L3MBTL1 | |
| SCHEMBL26501667 | 0.78 | NR1H4 (0.40) | — | |
| SCHEMBL26501695 | 0.78 | SMN1; SMN2 (0.40) | TDP1 | |
| SCHEMBL26501651 | 0.77 | DHFR (0.34) | — | |
| SCHEMBL26501559 | 0.77 | RAB9A (0.35) | TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, CYP11A1 | GLS 57/4885HTT 2621/4885PDE2A 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.